Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.AMR_Action_Fund
Fighting antibiotic resistance: Boehringer Ingelheim joins AMR Action FundCompany contributes USD 50 million to invest in antibiotic R&D within AMR Action FundAntimicrobial resistance (AMR) considered one of the most urgent global medical challengesJoint approach to combat the global threat of AMR (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2020 Category: Research Source Type: news
Numab
Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal DiseasesThe collaboration with Numab Therapeutics expands Boehringer Ingelheim ’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA)Numab ’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 7, 2020 Category: Research Source Type: news
ExternalInnovationHubChina
Boehringer Ingelheim Launches External Innovation Hub in China Boehringer Ingelheim is increasing its efforts to access external innovation in China, recognizing the opportunities offered by the prospering Chinese life science ecosystem, to develop new breakthrough medicines for patients with high unmet medical needsThe External Innovation Hub China formalizes these efforts by co-locating business leaders from Boehringer Ingelheim ’s partnering functions to facilitate access to a range of collaboration opportunities. Academic and biotech institutions will also have access to the Boehringer Ingelheim Venture Fund The...
Source: Boehringer Ingelheim Corporate News - July 2, 2020 Category: Research Source Type: news
CAROLINA-CARMELINA-Asia-analysis
Cardiovascular and renal safety profile of linagliptin demonstrated in Asian adults with type 2 diabetesIn a sub-analysis of the CAROLINA ® cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus glimepiride in Asian adults with type 2 diabetes and high cardiovascular risk1In addition, a sub-analysis of the CARMELINA ® cardiovascular outcome trial demonstrated a similar cardiovascular and renal safety profile for linagliptin versus placebo in Asian adults with type 2 diabetes and high cardiorenal risk2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 29, 2020 Category: Research Source Type: news
Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim ’s China-developed Classical Swine Fever live vaccine approvedBoehringer Ingelheim received a marketing authorization for Ingelvac ® CSF MLV, the first classical Swine Fever live vaccine jointly developed by a multinational company and Chinese research institutesThe company reaffirms its commitment to supplying innovative swine vaccines for the Chinese industry (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 25, 2020 Category: Research Source Type: news
EUbOPEN
New consortium EUbOPEN will provide tools to unlock disease biology66 million euros to generate open-access chemical tools (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 8, 2020 Category: Research Source Type: news
LastMile – improving through digital
“LastMile” – improving through digitalWith the new mobile app, the “LastMile” team can now better manage day-to-day activities and support farmers, retailers and veterinarians more effectively (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 4, 2020 Category: Research Source Type: news
CHMP_opinion_nintedanib_ILD_PF
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in mo...
Source: Boehringer Ingelheim Corporate News - May 29, 2020 Category: Research Source Type: news
DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of p...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news
Winners of 2020 BVDzero Case Awards
announcedBoehringer Ingelheim grants a total prize of 15,000 euros to the top 10 clinical casesThe company encourages the search for both clinical and subclinical cases of bovine viral diarrhea (BVD) in cattle herds, aiming to improve BVD awareness (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 25, 2020 Category: Research Source Type: news
AcquisitionOfNorthernBiologics
Boehringer Ingelheim Acquires Northern Biologics ’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio Acquisition provides assets targeting the tumor stroma and myeloid cellsThese new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim ’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers and myeloid cell modulators Acquisition of Versant-built company based in Toronto ’s MaRS Discovery District (Source: Boehrin...
Source: Boehringer Ingelheim Corporate News - May 14, 2020 Category: Research Source Type: news
GeographicAtrophyCollabortationWithCDR-Life
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness WorldwideThe collaboration with CDR-Life is the second strategic partnership within a year for Boehringer Ingelheim in retinal diseases, furthering the company ’s commitment to develop novel treatments and technologies for patients who have only inadequate treatment options Together the partners will advance CDR-Life ’s preclinical antibody fragments targeting a key pathway in geographic atrophy (GA) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 13, 2020 Category: Research Source Type: news
European_Commission_approves_nintedanibSSc-ILD
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need (Source: Boehringer Inge...
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news
PatientView survey
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey Boehringer Ingelheim among top ten most “patient-centric” pharma companies* (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo ® EquiHaler® wins Red Dot for outstanding design qualityBoehringer Ingelheim ’s Aservo® EquiHaler® wins the Red Dot Award: Product Design 2020Red Dot has become established internationally as one of the most sought-after seals of quality for excellent design (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news
